1-苄基-4-羟基哌啶-4-甲酰胺 | 27771-25-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-苄基-4-羟基哌啶-4-甲酰胺
• 英文名称: 1-benzyl-4-hydroxypiperidine-4-carboxamide
• CAS: 27771-25-1
• 化学式: C₁₃H₁₈N₂O₂
• 分子量: 234.298
• InChiKey: YZVZPVSOBJCEJS-UHFFFAOYSA-N

物化性质

• 沸点：
  461.7±45.0 °C(Predicted)
• 密度：
  1.235±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-苄基-4-羟基哌啶-4-甲酰胺 在 palladium on activated charcoal 硫酸 、 氢气 、 sodium carbonate 、 potassium iodide 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 生成 8-[4-(4-fluoro-phenyl)-4-oxo-butyl]-2-phenyl-1-oxa-3,8-diaza-spiro[4.5]decan-4-one
  参考文献：
  名称：

  Lecolier,S.; Trouiller,G., Chimica Therapeutica, 1969, vol. 4, p. 437 - 445

  摘要：

  DOI：
• 作为产物：
  描述：

  1苄基-4-氰基-4-羟基哌啶 在 硫酸 作用下， 反应 16.0h， 以52%的产率得到1-苄基-4-羟基哌啶-4-甲酰胺
  参考文献：
  名称：

  黑色素浓缩激素受体 1 (MCHR1) 拮抗剂喹唑啉衍生物的设计和优化

  摘要：

  黑色素浓缩激素（MCH）是能量稳态的重要介质，在代谢和中枢神经系统疾病中发挥作用。描述了作为 MCHR1 拮抗剂的新型喹唑啉衍生物的模型支持设计、合成和多参数优化（生物活性、溶解度、代谢稳定性、hERG）。举例说明了该系列先导化合物减肥原理的体内证明。开发了源自​​ β2-肾上腺素能受体 X 射线结构（包括细胞外环）的精制 hMCHR1 同源模型簇，并用于指导设计。

  DOI：

  10.1016/j.bmcl.2012.03.050

文献信息

• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• Phthalazine derivatives and remedies for erectile dysfunction
  申请人：Eisai Co., Ltd.

  公开号：US06498159B1

  公开（公告）日：2002-12-24

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1 and R2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1 is a chlorine atom, R2 is a methoxy group and Y is a 5- or 6-membered amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种邻苯二氮杂环化合物，作为下式所代表的勃起功能障碍的治疗剂，其药理学上可接受的盐或水合物： 其中R1和R2相同或不同，分别代表卤素原子、可能被卤素原子取代的C1到C4烷基、可能被卤素原子取代的C1到C4烷氧基或氰基；X代表氰基、硝基、卤素原子、可能被取代的羟基亚胺基团或可能被取代的杂芳基团；Y代表杂芳基团、可能被取代的芳基团、可能被取代的炔基团、烯基团、烷基团、可选择地取代的饱和或不饱和的4-至8-成员氨基环，且环状胺化合物是单环化合物、双环化合物或螺环化合物；l为1到3的整数；但在l为1或2的情况下，X为氰基、硝基或氯原子，R1为氯原子，R2为甲氧基团，Y为取代羟基的5-或6-成员氨基环的情况除外。
• [EN] ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS D'ISOXAZOLE CARBOXAMIDE ET LEURS UTILISATIONS
  申请人：NOVARTIS AG

  公开号：WO2020058913A1

  公开（公告）日：2020-03-26

  A compound of Formula (I) or or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: Formula (I) wherein R1 and Y are as defined herein.

  提供了一个化合物的化学式（I）或其药用盐，已被证明对治疗听力损失或平衡障碍有用：化学式（I），其中R1和Y的定义如下。
• 4,5-Disubstituted-2-aryl pyrimidines
  申请人：Maynard D. George

  公开号：US20050277654A1

  公开（公告）日：2005-12-15

  4,5-disubstituted-2-arylpyrimidines of Formula I and Formula II are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 4,5-disubstituted-2-arylpyrimidines, which are useful as probes for the localization of C5a receptors.

  提供公式I和公式II的4,5-二取代-2-芳基嘧啶，其中R1、R2、R3、R8、R9、A和Ar在此定义。这些化合物是C5a受体的配体。公式I和II的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含此类化合物的制药组合物，以及使用此类化合物治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的4,5-二取代-2-芳基嘧啶，用于定位C5a受体。
• Phthalazine compounds and therapeutic agents for erectile dysfunction
  申请人：Eisai Co., Ltd.

  公开号：US20030105074A1

  公开（公告）日：2003-06-05

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: 1 wherein R 1 and R 2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R 1 is a chlorine atom, R 2 is a methoxy group and Y is a 5- or 6-memberred amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种治疗勃起功能障碍的邻苯二氮杂环化合物，其化学式如下，其药理学上可接受的盐或水合物：1其中，R1和R2相同或不同，表示卤素原子、可能被卤素原子取代的C1到C4烷基、可能被卤素原子取代的C1到C4烷氧基或氰基；X表示氰基、硝基、卤素原子、可能被取代的羟肟基或可能被取代的杂环基；Y表示杂环基、可能被取代的芳基、可能被取代的炔基、烯基、烷基、可选取代的饱和或不饱和4-至8环胺环，所述的环胺化合物是单环化合物、双环化合物或螺环化合物；l是1到3的整数；但当l为1或2时，X为氰基、硝基或氯原子，R1为氯原子，R2为甲氧基，Y为取代有羟基的5-或6环胺环时，不在此范围内。